Market capitalization | $115.39m |
Enterprise Value | $119.71m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.23 |
P/S ratio (TTM) P/S ratio | 2.15 |
P/B ratio (TTM) P/B ratio | 167.97 |
Revenue growth (TTM) Revenue growth | 7.19% |
Revenue (TTM) Revenue | $53.57m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Champions Oncology, Inc.:
1 Analyst has issued a forecast Champions Oncology, Inc.:
Oct '24 |
+/-
%
|
||
Revenue | 54 54 |
7%
7%
|
|
Gross Profit | 24 24 |
16%
16%
|
|
EBITDA | 1.72 1.72 |
128%
128%
|
EBIT (Operating Income) EBIT | -0.35 -0.35 |
96%
96%
|
Net Profit | -0.60 -0.60 |
94%
94%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
Head office | United States |
CEO | Ronnie Morris |
Employees | 210 |
Founded | 1985 |
Website | www.championsoncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.